Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment
Anti-IL-4Rα treatment may be effective for patients with severe asthma who have chronic rhinosinusitis or high FeNO levels at baseline.
Authors
- Yusuke Hayashi (ORCID: https://orcid.org/0000-0001-5672-1497)
- Hisako Matsumoto (ORCID: https://orcid.org/0000-0002-8754-6318)
- Chie Yoshimura
- Toyohiro Hirai (ORCID: https://orcid.org/0000-0002-7431-9044)
- Naoya Tanabe (ORCID: https://orcid.org/0000-0002-7481-0212)
- Kota Murohashi (ORCID: https://orcid.org/0000-0002-2637-8218)
- Takeshi Kaneko (ORCID: https://orcid.org/0000-0001-9292-307X)
- Shinya TSUKAMOTO
- Hironobu Sunadome (ORCID: https://orcid.org/0000-0002-4617-2348)
- Yu Hara (ORCID: https://orcid.org/0000-0002-2574-2516)
- Atsuyasu Sato (ORCID: https://orcid.org/0000-0001-8068-9984)
- Shota Takahashi
- Satoshi Marumo (ORCID: https://orcid.org/0000-0003-0524-0508)
- Kyohei Morita
- Moon Hee Hwang
Institutions
- Kyoto University (JP)
- Kyoto University Hospital (JP)
- Osaka Red Cross Hospital (JP)
- Kitano Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Respiratory Investigation
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.resinv.2025.05.005
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- Japanese Respiratory Society